Navigation Links
Team demos safety of RNA therapy
Date:9/26/2007

CAMBRIDGE, MA -- Researchers from MIT, Alnylam Pharmaceuticals and other institutions have demonstrated the safety of a promising type of genetic therapy that could lead to treatments for a wide range of diseases such as cancer.

The work, which will be published in the Sept. 27 issue of Nature, describes a new approach to conducting the therapy. A paper in Nature last year reported that another commonly used approach caused fatalities in mice.

The research focuses on RNA interference, or RNAi, a key part of the body's genetic machinery. RNAi works by using short strands of RNA to block the expression of specific genes.

RNAi has huge potential as a therapeutic agent, said Daniel Anderson, a research associate at MIT's Center for Cancer Research and one of the authors of the new paper.

However, a paper published in Nature last year by a different team showed that large doses of one type of RNA used for RNAi, short hairpin RNA, disrupted another key RNA pathway, the microRNA pathway, and caused the mice in the study to die. That result worried some RNAi researchers, said Anderson.

That first paper demonstrated that short hairpin RNA could lead to mouse fatality, he said. Researchers were concerned that a second type of RNA, small interfering RNA (siRNA), would induce the same toxicity.

In the current study, the researchers demonstrated that siRNA did not have the same toxic effects as large doses of shRNA because it does not interfere with the microRNA pathway. Further, they achieved 80 percent silencing of target genes in mice and hamster liver cells.

Using chemically synthesized siRNA, you can deliver sufficient siRNA to achieve therapeutically valuable gene silencing, without interfering with the cell's endogenous microRNA, said David Bumcrot, a director of research at Alnylam (an MIT startup) and one of the authors of the paper.

The research team used a new RNA delivery system developed at MIT, the details of which will be published in another upcoming paper, to perform the RNA interference.

In many RNAi studies, including the one that the MIT/Alnylam team was following up on, researchers use retroviruses to deliver genes that code for short hairpin RNA, which is a precursor to siRNA. Once the gene is incorporated into the cell's DNA, short hairpin RNA is synthesized and transported from the cell nucleus to the cytoplasm for further processing.

The earlier study showed that large amounts of short hairpin RNA blocked the cell's ability to export microRNA, which uses the same export pathway. Without normally functioning microRNA, the mice died. Low doses of short hairpin RNA were not toxic, but the dosage is difficult to control because once the shRNA gene is incorporated into the DNA of the host cells, it is expressed for long periods of time, said Bumcrot.

In the current MIT/Alnylam study, siRNA was delivered directly to the cell cytoplasm, so it did not compete with the export of microRNA.

We wanted to demonstrate that if you go downstream of that (export) step in the pathway, you don't get interference with the microRNA pathway, said Bumcrot. With synthetic siRNAs, we deliver a defined dose and we know how long the effect lasts. If toxicity issues arise, dosing can be stopped at any time. It's much easier to control and, therefore, safer.


'/>"/>

Contact: Elizabeth Thomson
thomson@mit.edu
617-258-5402
Massachusetts Institute of Technology
Source:Eurekalert

Related biology technology :

1. Reforming FDA: Focus on safety, let market judge efficacy
2. Funds will support public safety communications interoperabilty
3. High interest forces delay in food safety symposium
4. Human factors and IT: Designing for patient safety
5. UW Medical Foundation CEO shares his vision on the state of health care and patient safety
6. UW symposium to explore impact of IT on improving quality, safety and cost of healthcare
7. Thompson receives leadership award for technology solutions for patient safety
8. The Genesis of Gendicine: The Story Behind the First Gene Therapy
9. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
10. TomoTherapy opens technical training center
11. TomoTherapy raises $223 million in IPO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... The Greater Gift Initiative, Inc , ... Compass Research . GGI's mission is to advance global health and highlight the ... need in honor of each clinical trial volunteer. The vision of GGI is to ...
(Date:2/23/2017)... SAN FRANCISCO , Feb. 23, 2017 /PRNewswire/ ... and Beyond Type 1, a not-for-profit advocacy and education ... announced a grant from Beyond Type 1 to support ... 1 and other insulin-requiring diabetes.  For ... stem cell-derived cell replacement therapies with a focus on ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... is has acquired Kendall Research Systems, LLC (KRS) clinical development program. ... develops neural interface technology for research and clinical applications. The terms of the ...
(Date:2/22/2017)... CINCINNATI , Feb. 22, 2017 Scientists ... drives inflammation and organ damage in Gaucher and maybe ... fewer risks and lower costs than current therapies. ... Children,s Hospital Medical Center , which also included investigators ... , report their data Feb. 22. The study ...
Breaking Biology Technology:
(Date:2/8/2017)... Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... today reported financial results for its quarter and year ended ... quarter of 2016 was $3.9 million compared to $6.9 million ... fourth quarter of 2016 was $0.6 million compared to $2.6 ... the fourth quarter of 2016 was $0.5 million, or $0.02 ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... billion by 2021 from $8.3 billion in 2016 at ... 2016 to 2021. Report Includes - An overview ... global market trends, with data from 2015 and 2016, ... 2021. - Segmentation of the market on the basis ...
(Date:2/7/2017)... York , February 7, 2017 ... ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the ... and electronic transaction processing services, is pleased to announce ... the Company. Effective January 31, 2017, ... Board of Directors, CEO and President.  An experienced payment ...
Breaking Biology News(10 mins):